The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Kate C. Tatham; Manu Shankar-Hari; Yaseen M. Arabi

doi:10.1007/s00134-021-06540-w

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Kate C. Tatham, Manu Shankar-Hari^*, Yaseen M. Arabi

^*Corresponding author for this work

Peter Gorer Department of Immunobiology

Research output: Contribution to journal › Editorial › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	1315-1318
Number of pages	4
Journal	Intensive Care Medicine
Volume	47
Issue number	11
DOIs	https://doi.org/10.1007/s00134-021-06540-w
Publication status	Published - 1 Oct 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00134-021-06540-w

Cite this

@article{08d9e03cd2a44cc48841500c455ea779,

title = "The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?",

author = "Tatham, {Kate C.} and Manu Shankar-Hari and Arabi, {Yaseen M.}",

note = "Funding Information: MS-H is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and social care. ",

year = "2021",

month = oct,

day = "1",

doi = "10.1007/s00134-021-06540-w",

language = "English",

volume = "47",

pages = "1315--1318",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer Verlag",

number = "11",

}

TY - JOUR

T1 - The REMDACTA trial

T2 - do interleukin receptor antagonists provide additional benefit in COVID-19?

AU - Tatham, Kate C.

AU - Shankar-Hari, Manu

AU - Arabi, Yaseen M.

N1 - Funding Information: MS-H is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and social care.

PY - 2021/10/1

Y1 - 2021/10/1

UR - http://www.scopus.com/inward/record.url?scp=85116508438&partnerID=8YFLogxK

U2 - 10.1007/s00134-021-06540-w

DO - 10.1007/s00134-021-06540-w

M3 - Editorial

AN - SCOPUS:85116508438

SN - 0342-4642

VL - 47

SP - 1315

EP - 1318

JO - Intensive Care Medicine

JF - Intensive Care Medicine

IS - 11

ER -

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

UN SDGs

Access to Document

Other files and links

Cite this